Passionate about Developing Therapies to Advance the Treatment of Gastrointestinal (GI) Disorders

Passionate about Developing Therapies to Advance the Treatment of Gastrointestinal (GI) Disorders

Millions of patients in the United States are living with serious, untreated, or inadequately controlled GI conditions. It is time to change that.

Our Company

We are a GI-focused company with products in development to treat serious conditions that affect patients and for which there are limited treatment options today.

Our Pipeline

Our pipeline consists of NG101 for the treatment of GLP-1 induced nausea and vomiting, and gastroparesis.

Advancing the Treatment
of Serious GI Disorders

Neurogastrx, Inc. is a privately held, late clinical-stage biopharmaceutical company that is focused on identifying and developing therapies for patients suffering from serious gastrointestinal (GI) diseases.
Neurogastrx, Inc.
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.